	ent #: F01-20	03-801
NIH NATIONAL CANCER INSTITUTE Center for Cancer Research	on #:	3
Clinical Site Delegation of Authority Log Effective	Date: 11JU	JL2023

Protocol Number:	
Site Name and Branch Name:	

- 1. Guidance on completing the Log In case of questions, consult 2A F01-203-S01 Clinical Site Delegation of Authority Log FAQs.
  - This Log is to be completed and signed **digitally**.
  - Enter the protocol number and site name and branch name.
  - List the names of all Site Staff, their respective roles (e.g., Principal Investigator (PI), Sub-Investigator, Pharmacist, Study Coordinator, Data Manager, Regulatory Coordinator, Research Nurse, Research Laboratory Technician), and the significant study-related duties/tasks delegated by the PI using the Task Codes.
    - Note: Include all Staff listed on Form FDA-1572 on this Log. Staff duties/tasks must remain within the scope of their professional licensure. Study-specific tasks may be added to the list of numbered task codes as needed.
    - Note: Staff duties/tasks delegated by the PI may not be performed if the Staff member's training documentation is not available for the following:

1 Pro	otocol	Al	so, as applicable:
1. 110		•	Dangerous Goods Handling or International Air Transport Association (IATA)
2. Hu	uman Subjects Protection (HSP)	•	Other specialized procedures, e.g., study product preparation
		•	Non-NIH PI and site Staff electronic data capture (EDC) system Users must provide a record of training
3. Go	Good Clinical Practice (GCP)		on the protocol-specific use of the EDC system. Required before site activation.

- All Staff listed on the Log must provide an electronic 'certified' digital signature, i.e., PIV card, to indicate an understanding of the responsibilities assigned.
- Provide the Start Date for delegated study duties/tasks. If a Site Staff member's duties/tasks change, enter the End Date, then add a new line with their updated duties/tasks and Start Date.
- Provide the End Date when the individual no longer performs a delegated duty/task or participates in the study. If blank, this indicates that the duties/tasks were conducted until the completion of the study (Date of PI End-of-Study declaration).
- An entry for named Staff is <u>not complete</u> without the PI's **digital signature and date**. This indicates that the PI confirms that the Staff member is authorized, trained appropriately for the role, and qualified to perform the duties/tasks assigned. PI retains the overall responsibility for the conduct of the clinical trial, including delegated duties/tasks.
- Retain the current Log and all previous original Log versions in the site study file. Update the Log as personnel, roles, and/or study tasks change.

NATIONAL CANCER INSTITUTE       Revision #: 3         Clinical Site Delegation of Authority Log       Effective Date: 11JUL2023		Office of Sponsor and Regulatory Oversight	Document #:	F01-203-S01
	NIH NATIONAL CANCER INSTITUTE Center for Cancer Research	Clinical Site Delegation of Authority Log	Revision #:	3
		Clinical Site Delegation of Authority Log	Effective Date:	11JUL2023

Protocol Number:	
Site Name and Branch Name:	

## 2. Completion instructions at the end-of-study

- Fill and sign digitally: If blank rows remain, enter NA or N/A in each unused Name, Role, and Task Codes cell.
- After reviewing all entries for accuracy at the end of the study, the PI will sign and date the Log in the designated area for the End-of-Study declaration.

## \*Task Code Key

<ol> <li>1.</li> <li>2.</li> <li>3.</li> <li>4.</li> <li>5.</li> <li>6.</li> <li>7.</li> <li>8.</li> <li>9.</li> <li>10</li> </ol>	Obtain inclusion/exclusion assessment Confirm eligibility criteria met Perform study product management, dispensing, accountability Perform study product dose administration Perform physical exam	<ol> <li>Assess AEs and SAEs</li> <li>Assess concomitant medications</li> <li>SAE form preparation – delegated to qualified personnel at PI discretion</li> <li>SAE form approval – delegated to a physician licensed to diagnose listed on the 1572</li> <li>Confirm response criteria met</li> <li>Evaluate test results, including labs, for clinical significance</li> <li>Enter eCRF data</li> <li>Review/confirm eCRF data</li> </ol>	<ol> <li>Address eCRF data queries</li> <li>Sign-off on eCRFs</li> <li>Coordinate IRB communications, submissions</li> <li>Maintain site essential regulatory document file</li> <li>Process and/or ship laboratory specimens</li> <li>Conduct quality assurance/quality control procedures</li> <li>Complete and sign the <u>OSRO SROS Source Location Record Form</u></li> </ol>
27 28	. Other:	30. Other:	34. Other:

	Office of Sponsor and Regulatory Oversight	Document #:	F01-203-S01
NIH NATIONAL CANCER INSTITUTE Center for Cancer Research	Clinical Site Delegation of Authority Log	Revision #:	3
	Clinical Site Delegation of Authority Log	Effective Date:	11JUL2023
		<u>L</u>	

Protocol Number:	
Site Name and Branch Name:	

Name	Role	Task Codes (per Key)	Staff Signature (Digital with Date)	Start Date	<b>PI Signature</b> (Digital with Date)	End Date	<b>PI Signature</b> (Digital with Date)
	Principal Investigator						

NATIONAL CANCER INSTITUTE Center for Cancer Research       Clinical Site Delegation of Authority Log       Revision #: 3         Effective Date:       11JUL2023			Office of Sponsor and Regulatory Oversight	Document #:	F01-203-S01
	NIH	NATIONAL CANCER INSTITUTE Center for Cancer Research	Clinical Site Delegation of Authority Log	Revision #:	3
			Clinical Site Delegation of Authority Log	Effective Date:	11JUL2023

Protocol Number:	
Site Name and Branch Name:	

Name	Role	Task Codes (per Key)	<b>Staff Signature</b> (Digital with Date)	Start Date	<b>PI Signature</b> (Digital with Date)	End Date	<b>PI Signature</b> (Digital with Date)

NATIONAL CANCER INSTITUTE Center for Cancer Research       Clinical Site Delegation of Authority Log       Revision #: 3         Effective Date:       11JUL2023		NATIONAL CANCER INSTITUTE Center for Cancer Research	Office of Sponsor and Regulatory Oversight	Document #:	F01-203-S01
	NIH		Clinical Site Delegation of Authority Log	Revision #:	3
			Clinical Site Delegation of Authority Log	Effective Date:	11JUL2023

Protocol Number:	
Site Name and Branch Name:	

Name	Role	Task Codes (per Key)	Staff Signature (Digital with Date)	Start Date	<b>PI Signature</b> (Digital with Date)	End Date	<b>PI Signature</b> (Digital with Date)

NATIONAL CANCER INSTITUTE Center for Cancer Research       Revision #:       3         Clinical Site Delegation of Authority Log       Effective Date:       11JUL2023		Office of Sponsor and Regulatory Oversight	Document #:	F01-203-S01
	NIH NATIONAL CANCER INSTITUTE Center for Cancer Research		Revision #:	3
		Clinical Site Delegation of Authority Log	Effective Date:	11JUL2023

Protocol Number:	
Site Name and Branch Name:	

## Principal Investigator END-OF-STUDY Declaration:

By signing below, I declare that the information documented on this Log is correct and that the study has ended.

PI Name: \_\_\_\_\_ Date: \_\_\_\_\_

Signature of Principal Investigator: